Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939029 · ClinicalTrials.gov registry record · Phase 2
Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
A Phase 2 study of Smokeless Tobacco Use, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00939029: Completed Phase 2 study of Smokeless Tobacco Use, sponsored by Mayo Clinic.
NCT00939029 is a Phase 2 study of Smokeless Tobacco Use that has completed, run by Mayo Clinic. The registered enrollment target is 52 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939029, a Phase 2 study of Smokeless Tobacco Use, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Smokeless tobacco use ("chewing") is associated with negative health effects. To date, no medications have been shown to help chewers quit long-term. High dose nicotine patch therapy may improve the chances that chewers can quit for good. If found to be effective, chewers may use this treatment to help them quit and reduce their risk for negative health effects.
Primary Outcome
7 day point prevalence abstinence at the end of treatment, biochemically confirmed by urinary anabasine \< 2 ng per ml
Conditions Studied
Interventions
- DRUG nicotine replacement therapy (nicotine patches)
- DRUG placebo NRT
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT00939029 record still lists
NCT00939029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Smokeless Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which nicotine replacement therapy (nicotine patches) is the first listed.
NCT00939029 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00939029 about?
NCT00939029 is a clinical study titled "Highdose Nicotine Patch Therapy for Smokeless Tobacco Use". Smokeless tobacco use ("chewing") is associated with negative health effects. To date, no medications have been shown to help chewers quit long-term. High dose nicotine patch therapy may improve the chances that chewers can quit for good. If found to be effective, chewers may use this treatment to h...
What is the current status of trial NCT00939029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-07. Estimated completion is 2013-06.
What conditions does trial NCT00939029 study?
This clinical trial studies the following conditions: Smokeless Tobacco Use.
What interventions are being tested in trial NCT00939029?
The interventions under investigation include: nicotine replacement therapy (nicotine patches) (DRUG), placebo NRT (DRUG).
Who is sponsoring clinical trial NCT00939029?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00939029 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00939029's enrollment target sits among peer trials
52 1181st of 2000 higher than 811 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia